Background: Selatogrel Outcome Study in suspected Acute Myocardial Infarction (SOS-AMI) Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction EudraCT Number: 2020-000983-41 (clinicaltrials.gov) Link Sponsor: Idorsia Pharmaceuticals Ltd Trial Status: Recruiting Enrolling Centers: Worldwide: 250/ 20 – 30 countries/ 14000 participants Core Study Team Basel:
© Christian Mueller, 2012 - 2022 │ DisclaimerImprintWebmaster │ Last Update: November 2022
Ina-Maria Ferel, Ph.D.
SOS-AMI
Svetlana Stanojkovic Karolina Kupska Michael Freese Hannah Wernicke